| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Collaboration arrangement revenue | $53.7M | $0+100.0% | -$6.7M | — |
| Research and development | $19.2M-60.2% | $48.1M+51.7% | $31.7M-67.7% | $98.4M |
| General and administrative | $17.7M-1.6% | $18.0M+81.9% | $9.9M-74.1% | $38.1M |
| Total operating expenses | $36.8M-44.3% | $66.1M+58.9% | $41.6M-69.5% | $136.5M |
| Income (loss) from operations | $16.9M+125.6% | -$66.1M-37.0% | -$48.3M+63.8% | -$133.3M |
| Change in fair value of convertible notes | $0-100.0% | $15.9M+356.6% | -$6.2M | — |
| Gain on sale of asset | $11.7M | $0 | — | — |
| Other income (expense), net | $1.2M-71.3% | $4.1M+303.2% | $1.0M-99.2% | $134.5M |
| Total other income (expense), net | $12.9M-35.5% | $20.0M+487.1% | -$5.2M | — |
| Income (loss) before provision for income taxes and loss from equity method investment | $29.8M+164.7% | -$46.1M+13.7% | -$53.4M | — |
| Provision for income taxes | $0+100.0% | -$21K+93.4% | -$318K+55.5% | -$715K |
| Loss from equity method investment | $0+100.0% | -$1.6M | $0+100.0% | -$5.5M |
| Net income (loss) | $29.8M+162.5% | -$47.7M+11.2% | -$53.7M-973.8% | -$5.0M |
| Net income (loss) per share- basic | $2420.00+147.3% | -$5120.00+96.7% | -$153960.00-170966.7% | -$90.00 |
| Net income (loss) per share- diluted | $2420.00+136.8% | -$6580.00+95.7% | -$153960.00-170966.7% | -$90.00 |
| Weighted-average common shares - basic | 12.30B+32.0% | 9.32B+2570.3% | 349.1M-99.4% | 57.40B |
| Weighted-average common shares - diluted | 12.31B+27.5% | 9.66B+2666.8% | 349.1M-99.4% | 57.40B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.